Structure-function relationships of factor Xa inhibitors: implications for the practicing clinician

被引：6

作者：

Steinberg, Benjamin A. ^{[1
,2
]}

Becker, Richard C. ^{[1
,2
]}

机构：

[1] Duke Univ, Med Ctr, Durham, NC 27715 USA

[2] Duke Clin Res Inst, Durham, NC USA

来源：

JOURNAL OF THROMBOSIS AND THROMBOLYSIS | 2014年 / 37卷 / 02期

关键词：

Factor Xa inhibitor; Structure; Function; Review; IN-VITRO; ANTITHROMBOTIC AGENT; ORAL ANTICOAGULANTS; HIGHLY POTENT; APIXABAN; WARFARIN; PHARMACOKINETICS; RIVAROXABAN; DISCOVERY; THROMBIN;

D O I：

10.1007/s11239-013-0991-z

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The recent development and approval of novel oral anticoagulants represents a significant success in the intelligent design of target-specific therapeutics. However, while these agents obviate many of the shortcomings of their predecessor (warfarin), they present novel challenges in pharmacologic management as well. Each was designed to have high oral bioavailability and high affinity for its target molecule, conveying significant anticoagulant effects. Yet, such unique drug-ligand binding, coupled with unfamiliar drug interactions and renal-based clearance, represent challenges to clinical management. The current review describes the development and pharmacokinetic properties of these agents, in the context of their clinical utility and pitfalls.

引用

页码：234 / 241

页数：8

共 38 条

[1] Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome [J].

Alexander, John H. ;

Lopes, Renato D. ;

James, Stefan ;

Kilaru, Rakhi ;

He, Yaohua ;

Mohan, Puneet ;

Bhatt, Deepak L. ;

Goodman, Shaun ;

Verheugt, Freek W. ;

Flather, Marcus ;

Huber, Kurt ;

Liaw, Danny ;

Husted, Steen E. ;

Lopez-Sendon, Jose ;

De Caterina, Raffaele ;

Jansky, Petr ;

Darius, Harald ;

Vinereanu, Dragos ;

Cornel, Jan H. ;

Cools, Frank ;

Atar, Dan ;

Luis Leiva-Pons, Jose ;

Keltai, Matyas ;

Ogawa, Hisao ;

Pais, Prem ;

Parkhomenko, Alexander ;

Ruzyllo, Witold ;

Diaz, Rafael ;

White, Harvey ;

Ruda, Mikhail ;

Geraldes, Margarida ;

Lawrence, Jack ;

Harrington, Robert A. ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (08) :699-708

[2] Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests A study in 9 Swiss laboratories [J].

Asmis, L. M. ;

Alberio, L. ;

Angelillo-Scherrer, A. ;

Korte, W. ;

Mendez, A. ;

Reber, G. ;

Seifert, B. ;

Stricker, H. ;

Tsakiris, D. A. ;

Wuillemin, W. A. .

THROMBOSIS RESEARCH, 2012, 129 (04) :492-498

[3] Pharmacokinetics, Biotransformation, and Mass Balance of Edoxaban, a Selective, Direct Factor Xa Inhibitor, in Humans [J].

Bathala, Mohinder S. ;

Masumoto, Hiroshi ;

Oguma, Toshihiro ;

He, Ling ;

Lowrie, Chris ;

Mendell, Jeanne .

DRUG METABOLISM AND DISPOSITION, 2012, 40 (12) :2250-2255

[4] Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor [J].

Becker, Richard C. ;

Yang, Hongqiu ;

Barrett, Yuchen ;

Mohan, Puneet ;

Wang, Jessie ;

Wallentin, Lars ;

Alexander, John H. .

JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2011, 32 (02) :183-187

[5] Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa) [J].

Connolly, Stuart J. ;

Eikelboom, John ;

Dorian, Paul ;

Hohnloser, Stefan H. ;

Gretler, Daniel D. ;

Sinha, Uma ;

Ezekowitz, Michael D. .

EUROPEAN HEART JOURNAL, 2013, 34 (20) :1498-1505

[6] Apixaban in Patients with Atrial Fibrillation [J].

Connolly, Stuart J. ;

Eikelboom, John ;

Joyner, Campbell ;

Diener, Hans-Christoph ;

Hart, Robert ;

Golitsyn, Sergey ;

Flaker, Greg ;

Avezum, Alvaro ;

Hohnloser, Stefan H. ;

Diaz, Rafael ;

Talajic, Mario ;

Zhu, Jun ;

Pais, Prem ;

Budaj, Andrzej ;

Parkhomenko, Alexander ;

Jansky, Petr ;

Commerford, Patrick ;

Tan, Ru San ;

Sim, Kui-Hian ;

Lewis, Basil S. ;

Van Mieghem, Walter ;

Lip, Gregory Y. H. ;

Kim, Jae Hyung ;

Lanas-Zanetti, Fernando ;

Gonzalez-Hermosillo, Antonio ;

Dans, Antonio L. ;

Munawar, Muhammad ;

O'Donnell, Martin ;

Lawrence, John ;

Lewis, Gayle ;

Afzal, Rizwan ;

Yusuf, Salim .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (09) :806-817

[7] Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].

Connolly, Stuart J. ;

Ezekowitz, Michael D. ;

Yusuf, Salim ;

Eikelboom, John ;

Oldgren, Jonas ;

Parekh, Amit ;

Pogue, Janice ;

Reilly, Paul A. ;

Themeles, Ellison ;

Varrone, Jeanne ;

Wang, Susan ;

Alings, Marco ;

Xavier, Denis ;

Zhu, Jun ;

Diaz, Rafael ;

Lewis, Basil S. ;

Darius, Harald ;

Diener, Hans-Christoph ;

Joyner, Campbell D. ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151

[8] Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties [J].

Corte, James R. ;

Fang, Tianan ;

Pinto, Donald J. P. ;

Han, Wei ;

Hu, Zilun ;

Jiang, Xiang-Jun ;

Li, Yun-Long ;

Gauuan, Jolicia F. ;

Hadden, Mark ;

Orton, Darren ;

Rendina, Alan R. ;

Luettgen, Joseph M. ;

Wong, Pancras C. ;

He, Kan ;

Morin, Paul E. ;

Chang, Chong-Hwan ;

Cheney, Daniel L. ;

Knabb, Robert M. ;

Wexler, Ruth R. ;

Lam, Patrick Y. S. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (09) :2845-2849

[9] THE COAGULATION CASCADE - INITIATION, MAINTENANCE, AND REGULATION [J].

DAVIE, EW ;

FUJIKAWA, K ;

KISIEL, W .

BIOCHEMISTRY, 1991, 30 (43) :10363-10370

[10] Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects [J].

Eerenberg, Elise S. ;

Kamphuisen, Pieter W. ;

Sijpkens, Meertien K. ;

Meijers, Joost C. ;

Buller, Harry R. ;

Levi, Marcel .

CIRCULATION, 2011, 124 (14) :1573-1579

← 1 2 3 4 →